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Abstract 24 
 25 
Episodic Ataxia type 2 (EA2) is a rare autosomal dominantly inherited neurological 26 
disorder characterized by recurrent disabling imbalance, vertigo and episodes of ataxia 27 
lasting minutes to hours. EA2 is caused most often by loss of function mutations of the 28 
calcium channel gene CACNA1A. In addition to EA2, mutations in CACNA1A are responsible 29 
for two other allelic disorders: familial hemiplegic migraine type1 (FHM1) and 30 
spinocerebellar ataxia type 6 (SCA6). Herein, we have utilised Next Generation Sequencing 31 
(NGS) to screen the coding sequence, exon-intron boundaries and UTRs of five genes where 32 
mutation is known to produce symptoms related to EA2, including CACNA1A. We performed 33 
this screening in a group of 31 unrelated patients with EA2 symptoms. Both novel and known 34 
mutations were detected through NGS technology, and confirmed through Sanger 35 
sequencing. Genetic testing showed in total 15 mutation bearing patients (48%), of which 9 36 
were novel mutations (6 missense and 3 small frameshift deletion mutations) and six known 37 
mutations (4 missense and 2 nonsense).These results demonstrate the efficiency of our NGS-38 
panel for detecting known and novel mutations for EA2 in the CACNA1A gene, also 39 
identifying a novel missense mutation in ATP1A2 which is not a normal target for EA2 40 
screening.  41 
 42 
 43 
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Introduction 52 
 53 
Episodic Ataxia type 2 (EA2) is an autosomal dominantly inherited paroxysmal 54 
cerebral disorder that demonstrates variable expressivity and starts in childhood or early 55 
adolescence (age range 2-32 years). EA2 is characterized by episodes of ataxia, vertigo and 56 
nausea lasting minutes to hours. The frequency of attacks ranges from once a year to four 57 
times a week. Attacks can be triggered by stress, exertion, caffeine, alcohol, fever, and heat. 58 
Acetazolamide (Griggs et al., 1978) and 4-aminopyridine (Strupp et al., 2004) have been 59 
shown to be effective in treating EA2, particularly in reducing attack frequency and severity. 60 
 61 
The CACNA1A gene (MIM: 601011) which covers 300 Kb with 47 exons, is located 62 
at chromosome 19p13 (Kramer et al., 1995, Teh et al., 1995) and is the only gene in which 63 
mutations are known to cause EA2 (Ophoff et al., 1996). The gene codes for the α1A pore-64 
forming subunit of Ca2+ voltage-gated Cav2.1 channels and is widely expressed throughout 65 
the central nervous system (CNS) (Mori et al., 1991, Westenbroek et al., 1995). It is involved 66 
in a variety of Ca2+ dependent processes, including mediating the entry of Ca2+ ions into 67 
excitable cells, muscle contraction, hormone or neurotransmitter release, and gene expression 68 
(Tsien et al., 1991). 69 
 70 
Mutations in the CACNA1A gene have been found to be responsible for three 71 
disorders with autosomal dominant inheritance: episodic ataxia type 2 (EA2; MIM: 108500), 72 
familial hemiplegic migraine type 1(FHM1; MIM: 141500) and spinocerebellar ataxia type 6 73 
(SCA6; MIM: 183086). Clinical overlap between the three disorders in terms of symptoms 74 
has been previously reported (Jodice et al., 1997, Mantuano et al., 2003, Romaniello et al., 75 
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2010). Nonsense mutations (Ophoff et al., 1996), deletions (Labrum et al., 2009, Riant et al., 76 
2008) and missense mutations in CACNA1A gene have all been found to lead to loss-of-77 
function of recombinant human CaV2.1 channels in heterologous expression systems found 78 
to cause EA2. 79 
 80 
Since the 1970s, most DNA diagnosis is undertaken by ‘gold standard’ traditional 81 
DNA Sanger sequencing. This is an accurate but slow and expensive means of diagnosis. 82 
Additionally, in order to avoid extensive costs to patients or health systems, the practice 83 
typically involves screening only regions where mutations are known, or more likely, to 84 
occur, limiting the ability of testing to identify unusual mutations causing disease. Those who 85 
fail initial screenings must thus go through additional rounds of testing. Therefore, testing for 86 
EA2 using Sanger sequencing is difficult, time consuming and expensive due to the number 87 
and size of sequences investigated. In contrast, Next Generation Sequencing (NGS) 88 
approaches have opened the door for massive parallel sequencing of targeted genes, as well 89 
as whole exome and whole genome sequencing. The AmpliSeq custom panel technique used 90 
here is an appropriate method to screen mutations in genes which cause clinically 91 
overlapping disorders. 92 
 93 
We have developed an AmpliSeq custom panel comprising the genes most related to 94 
episodic ataxia type2 and FHM in terms of causation of symptoms (CACNA1A, ATP1A2, 95 
SCN1A, NOTCH3 and KCNK18) in order to improve mutation detection. We screened a 96 
cohort of 31 unrelated patients with clinical diagnosis of EA2 for whom primary Sanger 97 
sequencing had failed to find a causative mutation using the Ion Torrent NGS platform. 98 
 99 
 100 
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MATERIALS AND METHODS 101 
 102 
Patients 103 
 104 
The Genomics Research Centre (GRC) diagnostics clinic began diagnostic testing in 105 
1999 and to date has tested approximately 730 patients for Episodic Ataxia type2 (EA2), 106 
Familial Hemiplegic Migraine (FHM) and cerebral autosomal dominant arteriopathy with 107 
subcortical infarcts and leukoencephalopathy (CADASIL). In the early stages of the clinic’s 108 
operation, causative mutations were identified using the traditional Sanger sequencing 109 
approach. During this period, DNA testing was undertaken in 167 EA2 patients according to 110 
the request of certified clinical neurologists around Australia and New Zealand. Of the 167 111 
patients that had been screened previously for mutations in selected exons in CACNA1A gene, 112 
few were found to have genetic aberrations. This prompted the development of the NGS test. 113 
From our 167 patients, 31 index cases underwent advanced testing, due to the presence of 114 
clinical EA symptoms without detection of genetic mutations by primary Sanger sequencing. 115 
 116 
Migraine Panel Characteristics and Ion Torrent Sequencing 117 
 118 
In the development of the panel, we chose 5 genes [Error! Reference source not 119 
found.] that were known to be involved in monogenic neurological disorders, including EA2. 120 
The ampliseq.com web designer was utilized to design primer pools to our specified genomic 121 
regions, according a reference human genome (hg 19 for our study). The primers for this 122 
panel of genes covers exonic regions, exon-intron boundaries as well as 3’ and5’ 123 
Untranslated Regions (UTRs). In total, this amounts to 34.9kb of sequencing region, with the 124 
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primers allowing for sequencing of 91.97% of our original target regions, using 274 primer 125 
pairs in two highly multiplexed reactions requiring only 10ng/reaction of input DNA per 126 
sample. 127 
 128 
In brief, sequencing of the amplified regions for the 31 genomic DNA samples were 129 
then conducted using the Ion AmpliSeq library kit (Life Technologies, Cat. no. 4480441 Rev 130 
A.0), followed by template preparation using the Ion OneTouch instrument (Life 131 
Technologies, Catalog Number 4480974 Rev 5.0), and finally were sequenced on the Ion 132 
Torrent Personal Genome Machine (PGM) using the sequencing 200 v2 kit protocols (Life 133 
Technologies, Catalog Number 4482006 Rev 3.0), all according to manufacturer instructions. 134 
One of 16 unique barcodes (Ion Xpress) was used to provide identification for each sample 135 
on a particular sequencing reaction. Library quality and quantity was assessed using the 136 
Agilent DNA High Sensitivity Bioanalyzer Kit. Two Ion 316 v2 Chips were used for 137 
sequencing allowing multiplexing of the 16 barcoded samples. The number of samples used 138 
per chip provided scope for around 100x read depth of coverage at each bases, allowing 139 
accurate detection of mutations. 140 
 141 
 142 
NGS Sequencing Analysis 143 
Data from the PGM runs were processed initially using the Ion Torrent platform-144 
specific pipeline software (Torrent Suite v4.0.2) to generate sequence reads, trim adapter 145 
sequences, filter, and remove lower-quality reads according to the BED file provided by 146 
AmpliSeq designer. Generated sequence files were aligned to the human complete genome 147 
(hg19). DNA and protein sequences from NGS and later Sanger sequencing were compared 148 
with the NCBI reference sequences (Pruitt et al., 2012), and the UCSC genome browser 149 
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(Dreszer et al., 2012). All rs ID numbers, locations, allele frequencies and genotypes for 150 
known variants were determined based on SNPs reported in dbSNP database (Sherry et al., 151 
2001) and further verified in the 1000 Genomes data sets. All variants detected were visually 152 
confirmed using the Integrative Genome Viewer (IGV2.3) software (Thorvaldsdottir et al., 153 
2013) and Ion Reporter Software (Life Technologies) were used to annotate the variants. 154 
 155 
All potentially causative mutations were further investigated by conventional Sanger 156 
Sequencing using standard protocols (Roy et al., 2012). Forward and reverse primer 157 
sequences for the validations are listed in [Error! Reference source not found.]. PCR 158 
products were used as templates for sequencing with BigDye Terminator reagents on a 3500 159 
DNA sequencing Analyzer (Life Technologies). Sanger sequence traces were aligned to the 160 
gene-specific reference sequence (NCBI build) using BLAST and CLUSTAL W, and 161 
visualised for manual verification of mutations and variants with Chromas 2.33 software. 162 
 163 
To predict the damaging effect of non-synonymous single nucleotide substitutions on 164 
protein structure, function, or phenotype, we used the available online tools, such as SIFT 165 
(Ng and Henikoff, 2001) (http://sift.jcvi.org/www/SIFT), Polyphen2 (Adzhubei et al., 2010) 166 
(http://genetics.bwh.harvard.edu/pph2/)  and finally Mutation Taster (Schwarz et al., 2010) 167 
(http://www.mutationtaster.org/). Each software package, was used to estimate the 168 
pathogenicity effect of every suspected variant, such as exonic nonsynonymous/synonymous, 169 
intronic and variants in the 5’ and 3’ untranslated regions, though SIFT and Polyphen2 only 170 
estimate pathogenicity based on coding sequence changes. 171 
 172 
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Where patients were also family members seeking confirmation of mutation status, 173 
segregation analysis for the available family members was conducted to further determine the 174 
impact of novel mutations/variants with the phenotype. 175 
Results 176 
 177 
Sequencing output analysis 178 
 179 
Genomic DNA from 31 patients with episodic ataxia type 2 phenotypes were 180 
sequenced using a NGS approach. Resultant Ion Torrent PGM sequence data was analysed 181 
using the Ion Torrent platform- specific software Torrent Suite v4.0.2 as detailed above. 182 
Sequencing via PGM generated an average sequencing of 3,136,750 total reads per Ion 316 183 
Chip, 455 Mb total bases detected, and 450 Mb of final readable data with 99% of total bases 184 
aligned to the human complete genome (hg19) and an average amplicon size of 147bp. 185 
 186 
The complete summary of data for each detected functional variant, mutation and 187 
amino acid neutral novel variant can be found in Error! Reference source not found.. 188 
 189 
Variants analysis 190 
 191 
Our panel sequences five genes associated with different neurological disorders 192 
including EA2, which all have overlapping phenotypes as part of our comprehensive 193 
diagnostics tool. 194 
After variant filtering, annotation, and interpretation, 127 different variants were 195 
identified among the 31 patients in the five sequenced genes with an average of 40 196 
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variants/patient. The bulk of these are unremarkable common SNPs and are not for clinical 197 
interest. In the following subsections, we will discuss the more unusual variants detected in 198 
these cases. 199 
Identification of known and novel mutations 200 
 201 
Nucleotide changes resulting in changes in highly conserved amino acid residues and 202 
predicted to be pathogenic with at least two of the prediction tools used, were considered to 203 
be mutations. 204 
 205 
In total, 15 of 31 (48.4%) of our patients carried probable disease-causing non-206 
synonymous, nonsense and small frameshift deletion mutations were identified in 207 
CACANA1A and ATP1A2 genes [Error! Reference source not found.].  As expected on the 208 
basis of the requested EA2 test, 14 of the 15 identified mutations were detected in the 209 
CACNA1A gene and only one was unexpectedly detected in ATP1A2 gene. 210 
 211 
Among the 14 detected mutations in the CACNA1A gene [Error! Reference source 212 
not found., Error! Reference source not found.&Error! Reference source not found.], 213 
five were previously described disease-causing mutations: two missense mutations in exon 12 214 
p.Glu533Lys (Scoggan et al., 2006), p.Gly540Arg (Rajakulendran et al., 2010); two missense 215 
mutations in exon 6 and13 (Cases13, 30), p.Asp302Asn (Burk et al., 2014) p.Arg583Gln 216 
(rs121908217) (Battistini et al., 1999, Cleves et al., 2010) and; the two nonsense mutations 217 
found in exon 27 and 37, p.Trp1448Ter (Jen et al., 2004) and p.Tyr1853Ter (Giffin et al., 218 
2002). 219 
 220 
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The remaining 8 mutations in CACNA1A were previously undescribed and estimated 221 
by the in silico tools as pathogenic. In the patients tested, there were three novel frameshift 222 
deletions: Case 17, c.928_931delACTG p.Thr310fs*5; Case 3, c.1672-223 
1_1675deletionGGTTA Val558Serfs*13; and case 8, c.1799_1800delTC p.Leu600fs*41 224 
detected in exon 6, 13 and 14 respectively. Other than the frameshifts, there were: Five novel 225 
non-synonymous mutations scattered throughout five different exons: in exon3 (Case 28) 226 
p.Gly162Val; in exon6 (Case 29) p.Arg279Cys; in exon8 (Case 24) p.Arg387Gly; in exon9 227 
(Case 27) p.Gly411Trp; and in exon34 (Case 9) p.Leu1749Pro. 228 
 229 
Interestingly, one novel mutation was identified in one of the 31 EA2 patients 230 
screened (Case 18) in exon13 of the ATP1A2 gene and (c.1709C>T, p.Thr570Met) and not 231 
the CACNA1A gene. Like the mutations detected in CACNA1A this ATP1A2 mutation was 232 
predicted to be deleterious by the three prediction tools used here. 233 
 234 
Identification of novel variants 235 
 236 
In addition, to the novel and known mutations identified in these cases, there were a 237 
number of novel non amino-acid changing variants identified. First, a synonymous novel 238 
variant in exon7 c.984C>T found in the same patient (Case 13) who was carrying a known 239 
mutation (p.Asp302Asn) and both the synonymous and non-synonymous variants were 240 
confirmed with Sanger in the index case and the available DNA of the only one family 241 
member also sent for testing (a brother). Similarly Case 29, was found to have a novel 242 
missense mutation (p.Arg279Cys) in CACNA1A gene in exon 6 along with novel potentially 243 
damaging 3’UTR variant [Error! Reference source not found.]. 244 
 245 
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Moreover, there were three unique variants identified in three different patients, the 246 
first (Case 19) was a predicted damaging synonymous variant detected in the NOTCH3 gene 247 
which shares the same chromosome as the CACNA1A gene, while an previously unknown, 248 
but predicted to be tolerated intronic variant was detected in CACNA1A in one patient (Case 249 
6) and finally, a new 3’UTR variant was detected (Case 10) in the ATP1A2 gene, also 250 
predicted to be tolerated by Mutation Taster software. 251 
 252 
Identification of rare SNPs 253 
 254 
In 10 of 16 cases for whom our panel couldn’t detect known or unknown 255 
mutations/damaging variants, several rare SNPs were detected, which are listed in [Error! 256 
Reference source not found.]. All have variable pathogenic effect when analysed by 257 
Mutation Taster software, most of them were unique to patients without any known or novel 258 
pathogenic genetic aberration identified in the five screened genes. 259 
 260 
Mutation validation and segregation analysis 261 
 262 
All known and novel mutations were further validated and confirmed with 263 
conventional Sanger sequencing [Error! Reference source not found.]. In four of the 15 264 
cases (Cases: 8, 13, 29, and 30), DNA samples from one of the patient’s parents or siblings 265 
was also requested for genetic testing in addition to the index case. Upon detection of the 266 
mutation in the index cases, these family members were also tested to help confirm mutation 267 
pathogenicity. Segregation of the individual mutations with similar phenotype as the index 268 
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case as noted in the testing request was confirmed within all four families (see schematic 269 
pedigree for novel mutations in Error! Reference source not found.). 270 
 271 
In summary, the mutational spectrum for EA2 patients comprised 6 known and 9 unknown 272 
mutations. Among them are three new small deletions (CACNA1A p.Thr310fs [4bp]; 273 
Val558Serfs*13 [5bp]; and p.Leu600fs [2bp]) and five new missense mutations all predicted 274 
to cause EA2. 275 
 276 
Clinical Context 277 
 278 
The clinical features varied among the 31 tested cases (18 males and 13 females). 279 
Frequency of attacks ranged from weekly to yearly attacks, and duration of attacks ranged 280 
from 30 minutes to hours, 12/31 had family history of a similar phenotype to the index case. 281 
Some cases had more extensive clinical symptoms than others [see Error! Reference source 282 
not found.] with examples of some of these outlined below: 283 
 284 
For case 6 (a 6 year old male); he presented with a clinical picture suggesting EA2. 285 
He had an episode of ‘encephalitis’ at 13 months of age associated with marked ataxia, which 286 
resolved over 3 months. Since then, he has had 4-5 episodes of ataxia associated with fever 287 
which resolved over several days. In the last described episode, he had severe ataxia with 288 
fever, marked truncal and gait ataxia and past pointing. He had a normal MRI result, but no 289 
response to Acetazolamide. A novel single base-pair exchange was identified in the 290 
CACNA1A gene (located in intron 44) in this patient, which is predicted to affect the 291 
CACNA1A protein through changes to mRNA splicing sites. 292 
 293 
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In case 8 (an 11 year old female), there were episodes of ataxia since the age of 10 294 
months, dizziness; visual symptoms; unsteadiness (inability to walk); nausea; vomiting and 295 
occasional headaches reported during the attacks, with complete resolution of symptoms 296 
typically taking 1-2 hours. Her mother (44 years of age) had similar attacks starting at an age 297 
of 5 years, improving as she got older, though pregnancies exacerbated her symptoms. 298 
During recent episodes of ataxia, she was unable to walk and suffered severe dysarthria. Both 299 
daughter and mother’s symptoms were relieved by Acetazolamide. A small frameshift 300 
deletion p.Leu600fs*41 [2bp] was identified using the NGS panel in the index case 301 
(daughter) and confirmed by Sanger sequencing in both the index case and her mother. 302 
 303 
In case 10 (a 37 year old female), there was at least a 3 year history of episodic acute 304 
onset ataxia associated with nausea and vomiting. She also had a history of migraine and 305 
recent daily attacks were reported. A new single nucleotide variant (SNV) in the 3’UTR in 306 
ATP1A2 gene was detected in this patient. 307 
 308 
In case 13, familial periodic ataxia (paralysis) and migraine were described in both 309 
index case (a 28 year old male), his brother (35 years of age) as well as their mother and all 310 
were known to respond to Acetazolamide. The brother was also diagnosed as having Charcot-311 
Marie-Tooth (CMT) neuropathy; pes cavus and with inability to walk on his heels but no 312 
muscle wasting. The amino acid changing p.Asp302Asn mutation and the new synonymous 313 
single nucleotide variant (Asn328Asn) in CACNA1A gene were both confirmed in both 314 
brothers. 315 
 316 
In case 19 (a 38 year old female), typical vertigo and abnormal nerve excitability were 317 
reported suggesting a clinical diagnosis of episodic ataxia or migraine vertigo. Although no 318 
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mutation was identified in this case, a novel non amino acid changing variant was detected in 319 
the NOTCH3 gene at the nucleotide position c.5640C>T (Val1880Val), which was 320 
computationally indicated to be potentially damaging. 321 
 322 
 323 
Discussion 324 
 325 
Autosomal dominant episodic ataxia type 2 (EA2) results from mutations of the 326 
CACNA1A gene, covering 300 kb with 47 exons. EA2 is caused by a wide range of mutations 327 
in CACNA1A, localized on chromosome 19p, which encodes the pore-forming α1A subunit of 328 
the CaV2.1 Ca
2+ channel (Ophoff et al., 1996). This subunit comprises four repeated domains 329 
(I-IV), and each domain contains six transmembrane regions (S1-S6) comprising a pore loop 330 
between S5 and S6.  In our tested patients, 5 of 15 mutations detected were involved in the 331 
pore loop regions of Domains I, III, and IV of the protein. Of these, three mutations were 332 
missense mutations in Cases 9, 13, and 29, one was a truncation mutation (Case 17) and one 333 
was a previously known nonsense mutation (p.Trp1448Ter) (Case 5) (Jen et al., 2004). It is 334 
worth noting that these mutations were spread throughout the gene.  This reinforces the 335 
difficulty in screening a few exons which harbor “hot spots” for mutation in the CACNA1A 336 
gene, an element compounded by symptomatic overlap between EA2 and other diseases. 337 
 338 
EA2 is mainly characterized by episodes of ataxia, vertigo and nausea lasting for 339 
minutes to hours, but a variety of overlapping clinical features with other dominant disorders 340 
like FHM1 and SCA6 have been previously described (Jodice et al., 1997, Mantuano et al., 341 
2003, Romaniello et al., 2010), such as dysarthria, diplopia, hemiplegia and headache (Jen et 342 
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al., 2004). Attacks are triggered by emotional stress, exertion, caffeine or alcohol in similar 343 
ways to these disorders and even common migraine. The issue with overlapping symptoms 344 
potentially confusing decisions relating to the clinical diagnosis of EA2  and treatment are 345 
exemplified in Case 18, in whom we identified a new missense mutation in the ATP1A2 gene 346 
(p.Thr570Met), instead of CACNA1A where one was expected to be found. This patient 347 
suffers from highly similar symptoms to EA2 (hence this being the requested test), and all 348 
episodes of their illness were resolved by using Acetazolamide treatment. This case’s result 349 
opens the door to potential clinical confusion in the precise differential diagnosis of EA2 350 
from FHM type 2, with response to acetazolamide not being a reliable indicator of having 351 
EA2. This also leads to potential to sequence incorrect genes to identify mutations, and while 352 
this may not always lead to delays in treatment, it does have the potential to limit family 353 
planning options for patients and the ability to diagnose other family members. 354 
 355 
Moreover, two of the known mutations presented here in two clinically diagnosed 356 
EA2 patients p.R583Q and p.Y1853* were previously described to be associated with both 357 
Familial Hemiplegic Migraine (FHM) and Episodic Ataxia2 (EA2).  In 1999, Battistini et al 358 
(Battistini et al., 1999) reported two sisters with p.Arg583Gln mutation who have typical 359 
hemiplegic migraine attacks associated with confusion and fever, accompanied with 360 
progressive cerebellar ataxia. In 2010, the same mutation was reported by Cleves et al 361 
(Cleves et al., 2010) in two sisters experiencing episodic ataxia without hemiplegia and 362 
confusion. In 2002, Giffin et al described a 3 year old male with FHM and ataxia symptoms 363 
linked to a nonsense mutation (p.Tyr1853Ter) in exon 37 in CACNA1A gene, the attacks 364 
being unresponsive to treatment with acetazolamide (Giffin et al., 2002).  In a similar 365 
overlapping case, the mutation p.Asp302Asn (reported here in Case 13) was reported  in 2014 366 
by Jaffer et al in a patient with episodic ataxia (www.scribd.com/doc/111991160/Untitled.), 367 
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while the same mutation was described by Bürk et al (2014) in a German patient with 368 
dominant cerebellar ataxia and absence of recurrent ataxic episodes (Burk et al., 2014). 369 
 370 
For the 16 patients for whom our panel failed to detect known or unknown mutation, 371 
we detected three previously unknown variants: in Case 6, an intronic single nucleotide 372 
variant (SNV) in CACNA1A gene; in Case 19, a synonymous variant in the NOTCH3 gene; 373 
and in Case 10, a single nucleotide variant found in the 3’untranslated region of ATP1A2. 374 
These variants have unknown pathogeniciy, and all but Case 19’s variant were predicted to 375 
be tolerated by the in silico tools. 376 
 377 
In addition, rare SNPs (<1% minor allele frequency) were also detected in 10/16 378 
cases, some of which might be involved with a patient’s individual phenotype. For instance, 379 
in Case 31, the unique amino acid changing p.Arg1917Cys at c.5749C>T (rs121917956) in 380 
the SCN1A gene is predicted to have a damaging effect when using PolyPhen-2 and Mutation 381 
Taster programs but is categorized by NCBI as a variant with an allele of uncertain 382 
significance. Therefore, further assessment for deleterious or disease causing effects using in 383 
silico methods of all novel variants might help to confirm the phenotype-genotype 384 
correlation. In addition, family segregation analyses may be needed to confirm the 385 
contribution of these variants to the patient’s phenotype. This may be especially important as 386 
such rare polymorphisms may effectively represent low penetrance mutations whose presence 387 
in disease carriers has gone unnoticed due to variable phenotype expression. 388 
 389 
Alternatively, it is possible that these rare polymorphisms do not contribute to disease 390 
phenotype and there are mutations in other genes responsible for their illnesses. Given our 391 
discovery of a gene causing a disease with EA2 symptoms in a patient bearing an ATP1A2 392 
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mutation, this seems likely, and perhaps the use of Whole Exome or Genome Sequencing 393 
approaches will enhance the probability of identifying new genes and/or mutations 394 
responsible for EA2 to allow future improvement of EA2 diagnostics. 395 
 396 
In terms of a diagnostics approach, the imprecise definitions of symptoms for the 397 
clinical diagnosis of EA2 and the large number of exons in the CACNA1A gene, make 398 
obtaining a clear clinical diagnosis using direct genetic testing using conventional Sanger 399 
sequencing for molecular diagnosis extremely difficult. Indeed, our detection of mutations in 400 
ATP1A2 potentially causing EA2 like symptoms strongly indicates that multiple gene 401 
screening could be a clinically valuable approach. Indeed, one might reasonably screen the 402 
other familial hemiplegic migraine genes FHM2 (ATP1A2), FHM3 (SCN1A) along with 403 
FHM1 (CACNA1A) in case these are responsible for EA2-like symptoms in a patient. 404 
 405 
With the number of the mutations identified in 15 of 31 (48.4%) of the EA2 patients 406 
tested our newly developed custom panel provides an improved diagnostics tool compared to 407 
traditional exon-by-exon sequencing widely used in laboratories to identify the genetic 408 
aberrations of patients sharing overlapping symptoms with EA2, such as FHM and SCA6. 409 
However, these results also indicated that there may be other EA2 genes yet to be identified 410 
and to be included on future diagnostic arrays. 411 
 412 
In comparison to panels with a very large number of genes or to Whole Exome 413 
Sequencing, the small number of genes in a disease-specific gene panel (such as our NGS 414 
multi-gene panel) allows a significant increase of coverage on target sequences and high read 415 
depth of all bases. This is a great help to reliably detect disease-causing mutations, as well as 416 
to limiting the detection and validation of large numbers of unclassified variants in different 417 
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genes which might not relate to the patient’s phenotypes. Moreover, high read depth for all 418 
the 15 mutations identified (>200x coverage depth) [Table3] and 100% concordance of the 419 
mutations detected by NGS panel with Sanger sequencing provides high confidence in 420 
mutation detection. This may enable elimination of Sanger sequencing to confirm the 421 
presence of the mutations if the coverage read depth is ≥100x, with Sanger confirmation 422 
perhaps reserved for less reliably detected mutations. Therefore, massively parallel 423 
sequencing of small panel genes should be considered as a screening tool to detect clear 424 
monogenic mutations of neurological disorders in which there is phenotypic and genotypic 425 
heterogeneity. Indeed, in an environment where whole exome and potentially whole genome 426 
sequencing is becoming more affordable, multi-gene panels may become the first stage in a 427 
genes-to-exome-to-genome approach to replace the older exon-by-exon sequencing using 428 
Sanger methods as the clinical standard method for genetic disease diagnosis. 429 
 430 
 431 
Conclusions 432 
 433 
We have developed a custom panel comprising 5 genes for daily routine genetic 434 
testing of Episodic Ataxia type 2 (EA2). The mutational spectrum identified in this study 435 
included fifteen different mutations (6 known and 9 unknown). Among them are three small 436 
deletions (CACNA1A p.Thr310fs*5 [4bp]; Val558Serfs*13 [5bp]; and p.Leu600fs*41 [2bp] 437 
which disrupt the reading frame and result in a premature stop of the CACNA1A protein at 438 
amino acid positions 314, 570, and  640 respectively, these were identified in exons 6, 13, 439 
and 14). The remaining CACNA1A  mutations were simple amino-acid substitutions. 440 
Additionally, a previously unknown mutation was identified in the ATP1A2 gene 441 
19 
 
p.Thr570Met in association with EA2 symptoms, confirming the difficulty to differentiate 442 
between the clinical features of EA2 and FHM for a precise clinical diagnosis. 443 
 444 
Based on this report, we felt that transitioning to an NGS platform that performs 445 
parallel sequencing enables much more cost-effective diagnosis and a more comprehensive 446 
diagnostics test, involving an interrogation of all implicated and related genes 447 
simultaneously. This provides the opportunity to identify novel and unexpected mutations 448 
increasing diagnostic capability. This approach reduces the difficulty for clinicians in 449 
choosing the genes to investigate due to the symptom overlap in relation to severe migraine 450 
related disorders, with the added consequence of keeping patient costs down. 451 
 452 
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 565 
Figure Legends 566 
Figure 1: Sequences of the eight novel genetic variants in CACNA1A gene identified by 567 
next generation sequencing. Five heterozygous exonic missense point mutations (A) in exon 568 
3; (B) in exon 6; (D) in exon 8; (E) in exon 9; and (H) in exon 34. Three small frameshift 569 
deletion mutations (C) in exon 6; (F) in exon13; and (G) in exon 14.  570 
 571 
 572 
Figure 2: Mutations in the α 1 A subunit of the voltage-gated Cav2.1 Ca 2+ channel 573 
encoded by EA2 CACNA1A gene. The protein is located in the plasma membrane and 574 
contains four repeated domains (I-IV), each encompassing six transmembrane segments (S1-575 
6). ○= Known mutations, ●= Novel mutations. Numbers in the symbol correspond to the 576 
mutation listed in order. 577 
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